A GGT-responsive tumor-penetration-enhancing fluorescent probe, its preparation and application

By designing GGT-responsive fluorescent probes and utilizing the hydrolysis reaction of GGT in the tumor microenvironment to enhance tumor permeability and fluorescence signal, the problems of low accumulation efficiency and unclear boundary identification in tumor imaging are solved, achieving high-precision tumor imaging and intraoperative navigation.

CN123106729APending Publication Date: 2026-11-17ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611621560.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-10-20
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing fluorescent probes suffer from problems such as low tumor accumulation efficiency, difficulty in deep imaging, unclear tumor boundary identification, and signal heterogeneity in tumor imaging, which affect diagnostic accuracy and the accuracy of intraoperative navigation.

Method used

A γ-glutamyl transpeptidase (GGT) responsive fluorescent probe was designed, comprising an aza-BODIPY fluorescent core, a short polyethylene glycol linker segment, and a GGT hydrolysis-responsive fragment. The probe utilizes the high expression of GGT in the tumor microenvironment to hydrolyze the GGT, thereby enhancing tumor permeability and fluorescence signal.

Benefits of technology

It achieves rapid internalization and deep penetration of tumor cells, can clearly identify tumor boundaries, improve imaging accuracy and intraoperative navigation accuracy, and has rapid metabolism and good biocompatibility.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106729A_ABST
    Figure CN123106729A_ABST
Patent Text Reader

Abstract

This invention discloses a GGT-responsive fluorescent probe for enhanced tumor penetration, its preparation, and its application. The fluorescent probe uses Aza-BODIPY as its fluorescent core, and its hydrophilic segments and GGT-responsive hydrolytic fragments are modified by click chemistry, as shown in formula (I). In the tumor microenvironment, the fluorescent molecules are specifically cleaved by highly expressed GGT, exposing amino groups that significantly enhance their affinity for tumor cell membranes and their ability to penetrate deep into tissues. Experimental results show that this probe can achieve precise tumor imaging and accurate visualization of tumor boundaries within 30 minutes of administration, and it also exhibits rapid blood clearance and excellent biocompatibility. This invention provides an efficient diagnostic and therapeutic tool for improving the accuracy of tumor imaging.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of medical technology, specifically to a γ-glutamyl transpeptidase (GGT)-responsive fluorescent probe for enhanced tumor penetration, its preparation method, and its application in tumor imaging. Background Technology

[0002] Fluorescence imaging, as an emerging molecular imaging method, is widely used in preclinical tumor research and intraoperative navigation due to its unique advantages. Specifically, compared with traditional imaging techniques such as magnetic resonance imaging (MRI) and computed tomography (CT), fluorescence imaging technology has advantages such as high sensitivity, high spatiotemporal resolution, ease of operation, and low imaging cost, making it suitable for clinical applications. For example, indocyanine green (ICG) is used for clinical imaging and intraoperative fluorescence navigation; its dynamic real-time imaging advantage can provide timely feedback during surgery, improving surgical precision.

[0003] Currently, most commonly used fluorescent probes are organic small molecule dyes or nanocarrier-loaded fluorescent probes, which have the advantages of high fluorescence intensity and good biocompatibility, and have become one of the core methods for tumor visualization. However, commonly used fluorescent probes often lack specificity, resulting in a low signal-to-noise ratio (SNR) in imaging, affecting diagnostic results. To overcome this deficiency, various tumor microenvironment-responsive fluorescent probes have been developed in recent years. These probes are activated by specific signals in the tumor microenvironment, such as pH response, ROS response, and enzyme response, reducing background signals and achieving specific signal amplification (LiH, et al . Near-Infrared (NIR) Fluorescence-Emitting SmallOrganic Molecules for Cancer Imaging and Therapy. Chem Soc Rev , 2022, 51 (21):8957-9008.).

[0004] Although responsive fluorescent probes have significantly improved the signal-to-noise ratio of tumor imaging, the high interstitial pressure, dense matrix, and abnormal vascular network of tumor tissue form a series of physical barriers (Chauhan VP, et al . Strategies for Advancing Cancer Nanomedicine. Nature Mater , 2013, 12 (11): 958-962.;SunQ, et al. Rational Design of Cancer Nanomedicine: Nanoproperty Integration andSynchronization. Advanced Materials (2017, 29 (14): 1606628.), which results in low tumor accumulation efficiency of fluorescent probes and limits the probes mainly to the vicinity of tumor vessels. This superficial distribution often creates imaging blind spots, causing the core area of ​​heterogeneous solid tumors to lack signal, leading to false negative results. In addition, the superficial accumulation of probes on the tumor surface makes the signal gradient at the junction of tumor and normal tissue become gentle. This blurred boundary directly reduces the accuracy of intraoperative navigation and increases the risk of tumor recurrence. At the same time, the problem of uneven signal intensity will also reduce the SNR to some extent. The existence of these problems limits the further application of fluorescent probes.

[0005] Therefore, developing a fluorescent probe that can cross the tumor barrier, image deep tumors, and clearly identify tumor boundaries is of great significance to the field of tumor diagnosis. Summary of the Invention

[0006] The purpose of this invention is to provide a fluorescent probe that can quickly identify tumor boundaries and enhance penetration within the tumor, and to apply it to tumor fluorescence imaging and intraoperative navigation.

[0007] To achieve the above objectives, the present invention adopts the following technical solution: This invention provides a γ-glutamyl transferase (GGT)-responsive fluorescent probe with enhanced tumor penetration, the molecular structure of which is shown in Formula (I). (Ⅰ), Where n is between 2 and 20.

[0008] The fluorescent probe provided by this invention comprises a nitrogen-acidified BODIPY fluorescent core and a short polyethylene glycol linker segment [-(CH2CH2O)]. n The probe consists of three parts: [-CH2CH2-] and a γ-glutamyl transpeptidase (GGT) hydrolysis response fragment. The aza-BODIPY fluorescent core imparts near-infrared fluorescence to the probe; the polyethylene glycol linker enhances the hydrophilicity of the fluorescent probe through hydrogen bonding; the GGT hydrolysis fragment can be catalyzed by the highly expressed GGT in tumors to hydrolyze γ-glutamyl, exposing an amino group. In the slightly acidic environment of the tumor microenvironment, this amino group easily becomes positively charged, and then rapidly internalizes into the tumor under electrostatic adsorption, enhancing intratumoral permeability.

[0009] The present invention demonstrates that, compared with fluorescent probes without GGT hydrolysis response fragments, the fluorescent probes provided by the present invention exhibit stronger tumor cell uptake efficiency and tissue penetration ability.

[0010] Preferably, n is 3. The specific structural formula is shown in equation (Ⅱ). (II)

[0011] The present invention also provides a method for preparing the fluorescent probe, the method comprising the following steps: (1) Under alkaline conditions, Aza-BODIPY undergoes a nucleophilic substitution reaction with tert-butyl bromoacetate, followed by deprotection with trifluoroacetic acid to obtain BOD-COOH with a carboxyl group modification; subsequently, it reacts with terminal azidated polyethylene glycolamine (general formula NH2-(CH2CH2O)). n -CH2CH2N3, where n is 2~20, undergoes an amidation reaction to give BOD-N3; (2) Boc-L-2-aminobutyric acid undergoes an amidation reaction with but-3-yn-1-amine, followed by deprotection with trifluoroacetic acid to obtain an intermediate product, which then undergoes an amidation reaction with Boc-L-glutamic acid-1-tert-butyl ester, and after deprotection, GGT-responsive hydrolysis molecules are obtained. (3) The fluorescent probe was prepared by reacting BOD-N3 with GGT-responsive hydrolysate via an azide-alkyne cycloaddition reaction.

[0012] In step (1), short polyethylene glycol linking segments and click reaction sites were introduced into the fluorescent dye aza-boron dipyrrole methylene (Aza-BODIPY) to modify the structure of the prepared BOD-N3 as shown in formula (Ⅲ). (Ⅲ), Where n is between 2 and 20.

[0013] The BOD-N3 comprises three parts: a nitrogen-containing BODIPY fluorescent core, a hydrophilic chain, and a click reaction site. The azide portion is used for subsequent azide-alkyne cycloaddition reactions.

[0014] In one specific embodiment of the present invention, BOD-N3 is prepared by reacting BOD-COOH with 1-amino-11-azido-3,6,9-trioxaundecan via an amidation reaction.

[0015] In step (2), a GGT-responsive hydrolysis molecule for the azide-yne ​​cycloaddition reaction is prepared, the structural formula of which is shown in formula (Ⅳ). (Ⅳ).

[0016] Preferably, in steps (1) and (2), prior to the amidation reaction, BOD-COOH, Boc-L-2-aminobutyric acid, or Boc-L-glutamic acid-1-tert-butyl ester is activated with N,N′-carbonyldiimidazole to form a carboxyl group.

[0017] In step (3), GGT-responsive hydrolysis molecules are modified onto BOD-N3 by copper-catalyzed azide-alkyne cycloaddition reaction to obtain the fluorescent probe BOD-GGT with the structure shown in formula (I).

[0018] Specifically, the fluorescent probe BOD-GGT was prepared by dissolving BOD-N3, GGT-responsive hydrolysate, cuprous iodide, and sodium ascorbate in anhydrous dimethyl sulfoxide and reacting at room temperature.

[0019] The fluorescent probe BOD-GGT provided by this invention has active permeation function, allowing it to be rapidly internalized by GGT-expressing tumor cells. Fluorescence imaging enables the labeling of tumor cells. Its excitation wavelength is approximately 700 nm, and its emission wavelength is approximately 735 nm. Furthermore, due to its small molecular weight, the fluorescent probe is rapidly metabolized by the system. Studies show that the fluorescence signal of the fluorescent probe BOD-GGT in major organs decreases over time, and no significant pathological abnormalities in major organ tissues were observed within the experimental dosage and observation period.

[0020] Another object of the present invention is to provide the application of the fluorescent probe in the preparation of tumor imaging reagents, wherein the optimal excitation wavelength of the fluorescent probe is about 700 nm and the optimal emission wavelength is about 735 nm.

[0021] Preferably, the tumor imaging reagent comprises the fluorescent probe and a pharmaceutically acceptable solvent, wherein the solvent is water, physiological saline, a buffer solution, or an aqueous solution containing 1%-20% by volume of an organic co-solvent. Specifically, the organic co-solvent is dimethyl sulfoxide.

[0022] Preferably, the tumor imaging reagent is used to prepare tumor diagnostic kits or intraoperative navigation kits. The kits are used for: real-time identification of tumor boundaries, detection of micrometastases, or to assist in surgical resection.

[0023] Preferably, the tumor imaging reagent is an intravenous injection preparation or a spray.

[0024] The application procedure of the tumor imaging reagent includes: administering the fluorescent probe or imaging reagent to the tumor area by intravenous injection or in situ spraying, and performing fluorescence detection after 10-60 minutes.

[0025] As a specific embodiment of the present invention, the tumor imaging reagent can be used for in vivo imaging of mice via intravenous administration.

[0026] In one specific embodiment of the present invention, during tumor surgery, the tumor imaging reagent is applied to the tumor region via in-situ spraying to identify tumor boundaries in real time and achieve intraoperative navigation. Animal experiments have shown that spraying administration can rapidly mark tumor boundaries and improve the signal-to-noise ratio of tumor imaging.

[0027] In one specific embodiment of the present invention, the tumor is a tumor with high GGT expression. The fluorescent probe provided by the present invention can be rapidly internalized by tumor cells with high GGT expression, enabling fluorescence imaging of tumor cells with high GGT expression.

[0028] Specifically, the tumor can be, but is not limited to, pancreatic cancer. Cellular and animal experiments have shown that the fluorescent probe provided by this invention can be rapidly internalized by pancreatic cancer cells with high GGT expression within 5 minutes, deeply penetrating tumor tissue and exhibiting excellent retention effects within the tumor.

[0029] The beneficial effects of this invention are as follows: This invention provides a fluorescent probe, BOD-GGT, with active penetration capability. In the tumor microenvironment, it is specifically cleaved by highly expressed GGT, exposing amino groups and significantly enhancing its affinity for tumor cell membranes and its ability to penetrate deep into tissues. Experimental results show that the fluorescent probe can be rapidly internalized by GGT-highly expressing tumor cells, penetrating into the tumor spheroid and enabling imaging of GGT-highly expressing tumor cells. This probe achieves precise tumor imaging and accurate visualization of tumor boundaries within 30 minutes of administration, and exhibits rapid blood clearance and excellent biocompatibility. Therefore, this novel penetrating fluorescent probe can be used for tumor imaging and intraoperative tumor navigation. This invention provides an efficient diagnostic and therapeutic tool for improving the accuracy of tumor imaging and has excellent application prospects. Attached Figure Description

[0030] Figure 1 This is a schematic diagram of the synthetic route for Aza-BODIPY click site modification in Example 1.

[0031] Figure 2 This is a schematic diagram of the synthetic route for the hydrolyzable GGT fragment in Example 1.

[0032] Figure 3 This is a schematic diagram of the synthesis routes of the fluorescent probe BOD-GGT and the control BOD-PEG in Example 1.

[0033] Figure 4 The image shows the 1H NMR spectrum of the fluorescent probe BOD-GGT synthesized in Example 1.

[0034] Figure 5 Absorption spectral analysis of BOD-GGT synthesized in Example 1.

[0035] Figure 6 The linear fitting curve between the concentration and absorbance of BOD-GGT synthesized in Example 1 is shown.

[0036] Figure 7 Emission spectral analysis of BOD-GGT synthesized in Example 1.

[0037] Figure 8 The figure shows the enzyme digestion results of the hydrolyzable GGT fragment synthesized in Example 1. From top to bottom, the figure shows the schematic diagram of the enzyme digestion route, the 1H NMR spectrum before enzyme digestion, and the 1H NMR spectrum after enzyme digestion.

[0038] Figure 9 This shows the results of a rapid cell entry experiment of the fluorescent probe into BxPC-3 cells.

[0039] Figure 10 The results of fluorescent probe uptake experiments are shown in different cell lines. In the figure, **** indicates a significant difference between the BxPC-3 cell group incubated with the BOD-GGT probe (Bx-GGT) and the other groups. p <0.0001.

[0040] Figure 11 The results show the penetration of the fluorescent probe into BxPC-3 cell spheres.

[0041] Figure 12 Figure 11 shows the quantitative distribution curve of fluorescence intensity (grayscale value) of the fluorescent probe along the diameter scan line inside the tumor sphere.

[0042] Figure 13 The results are from in vivo imaging experiments at different time points after intravenous injection of fluorescent probes into tumor-bearing mice.

[0043] Figure 14 for Figure 13 The results are presented in a statistical graph. **** in the graph indicates a significant difference between the two groups at 0.5 h. p <0.0001.

[0044] Figure 15 The results show the organ distribution at different time points after intravenous injection of the fluorescent probe.

[0045] Figure 16 for Figure 15 Statistical chart of the results.

[0046] Figure 17 The results are from a plasma clearance experiment following intravenous injection of a fluorescent probe.

[0047] Figure 18 The results show the intraoperative navigation experiment after the fluorescent probe was sprayed into the subcutaneous tumor of tumor-bearing mice.

[0048] Figure 19 Images of major organs of mice after intravenous injection of a fluorescent probe, stained with hematoxylin and eosin (HE). Detailed Implementation

[0049] The present invention will be further described below with reference to specific embodiments. These embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Any modifications or substitutions made to the methods, steps, or conditions of the present invention without departing from the spirit and essence of the invention are within the scope of the invention.

[0050] Unless otherwise specified, the experimental methods used in the following examples are conventional methods; the materials and reagents used are commercially available unless otherwise specified.

[0051] tert-butyl bromoacetate (CAS No.: 5292-43-3), anhydrous potassium carbonate (CAS No.: 584-08-7), N,N'-carbonyldiimidazole (CAS No.: 530-62-1), 11-azido-3,6,9-trioxaundecan-1-amine (CAS No.: 134179-38-7), 2-[2-[2-(2-prop-1-yloxy)ethoxy]ethoxy]ethanol (CAS No.: 208827-90-1), but-3-ynyl-1-amine (CAS No.: 14044-63-4) Boc-L-2-aminobutyric acid (CAS No.: 34306-42-8), Boc-L-glutamic acid-1-tert-butyl ester (CAS No.: 24277-39-2), cuprous iodide (CAS No.: 7681-65-4), and sodium L-ascorbate (CAS No.: 134-03-2) were purchased from Anaiji Chemical; BxPC-3 cells and NIH-3t3 cells were purchased from ATCC; GGsTop (CAS No.: 926281-37-0) was purchased from MCE; and γ-glutamyl transpeptidase was purchased from Yuanye Biotechnology.

[0052] Example 1: Synthesis and Characterization of Fluorescent Molecule BOD-GGT 1. Synthesize Aza-BODIPY This step is referenced in (Murtagh J, et al . Azide Conjugatable and pH ResponsiveNear-Infrared Fluorescent Imaging Probe. Org Lett (2009, 11(23): 5386-5389.) The unmodified NIR fluorescent probe Aza-BODIPY was obtained, with the following structural formula: .

[0053] 2. Aza-BODIPY Click Site Modification Synthesis route diagram as follows Figure 1 As shown.

[0054] Aza-BODIPY (1.06 g, 2 mmol), tert-butyl bromoacetate (1.16 g, 6 mmol), and anhydrous potassium carbonate (0.83 g, 6 mmol) were added to a single-necked flask, dissolved in an appropriate amount of anhydrous acetonitrile, and refluxed at 80 °C overnight. After the reaction was complete, the mixture was filtered, and the filtrate was purified by silica gel column chromatography with ethyl acetate:dichloromethane (1:20, v / v) as the mobile phase. The purified filtrate was dried under reduced pressure to obtain a dark green substance. After redissolving in dichloromethane, trifluoroacetic acid was added, and the mixture was reacted at room temperature for 2 h to remove the tert-butyl ester protection. The purified filtrate was dried under reduced pressure to obtain BOD-COOH.

[0055] BOD-COOH (680 mg, 1.05 mmol) and N,N'-carbonyldiimidazole (486 mg, 3 mmol) were added to a single-necked flask and dissolved in an appropriate amount of anhydrous dichloromethane. The reaction was carried out at room temperature for 2 h. After confirming the complete reaction of BOD-COOH by TCL monitoring, 11-azido-3,6,9-trioxaundecan-1-amine (480 mg, 2.2 mmol) was added, followed by a few drops of triethylamine. The reaction was carried out overnight at room temperature. After the reaction was completed, the mixture was washed with water and extracted with dichloromethane, repeated three times. The organic phase was dehydrated with anhydrous sodium sulfate, concentrated by rotary evaporation, and purified by silica gel column chromatography with ethyl acetate:dichloromethane (1:1, v / v) as the mobile phase. After drying, BOD-N3 was obtained.

[0056] 3. Synthesis of hydrolyzable GGT fragments Synthesis route diagram as follows Figure 2 As shown.

[0057] Boc-L-2-aminobutyric acid (2.01 g, 10 mmol) and N,N'-carbonyldiimidazole (2.43 g, 15 mmol) were added to a single-necked flask, dissolved in anhydrous dichloromethane, and reacted at room temperature for 2 h. After the reaction of Boc-L-2-aminobutyric acid was confirmed to be complete by TCL monitoring, but-3-yn-1-amine (0.83 g, 12 mmol) was added, followed by 5 mL of triethylamine, and the reaction was carried out overnight at room temperature. After the reaction was completed, the mixture was washed with water and extracted with dichloromethane, repeated three times. The organic phase was dehydrated with anhydrous sodium sulfate, concentrated by rotary evaporation, purified by silica gel column chromatography with ethyl acetate:dichloromethane (1:5, v / v) as the mobile phase, and dried under reduced pressure. After redissolving in dichloromethane, trifluoroacetic acid was added, and the mixture was reacted at room temperature for 2 h to remove Boc protection. The product was dried under reduced pressure to give the intermediate 2-amino-N-(but-3-yn-1-yl)butyramide.

[0058] Boc-L-glutamic acid-1-tert-butyl ester (1.82 g, 6 mmol) and N,N'-carbonyldiimidazole (1.46 g, 9 mmol) were added to a single-necked flask, dissolved in an appropriate amount of anhydrous dichloromethane, and reacted at room temperature for 2 h. After the reaction of Boc-L-glutamic acid-1-tert-butyl ester was confirmed to be complete by TCL monitoring, 2-amino-N-(but-3-yn-1-yl)butanamide (1.11 g, 7.2 mmol) was added, followed by 5 mL of triethylamine, and the reaction was carried out overnight at room temperature. After the reaction was completed, the mixture was washed with water and extracted with dichloromethane, repeated three times. The organic phase was dehydrated by anhydrous sodium sulfate, concentrated by rotary evaporation, and purified by silica gel column chromatography with ethyl acetate:dichloromethane (1:1, v / v) as the mobile phase. The solid was dried under reduced pressure to obtain a white solid. After redissolving in dichloromethane, trifluoroacetic acid was added, and the mixture was reacted at room temperature for 2 h to remove Boc and carboxy-tert-butyl ester protection. The solid was dried under reduced pressure to obtain the hydrolyzable GGT fragment.

[0059] 4. The azide-yne ​​cycloaddition reaction yields BOD-GGT. Synthesis route diagram as follows Figure 3 As shown.

[0060] BOD-N3 (155 mg, 0.15 mmol), a hydrolyzable fragment of GGT (226 mg, 0.8 mmol), cuprous iodide (76 mg, 0.4 mmol), and sodium ascorbate (158 mg, 0.8 mmol) were added to a single-necked flask, dissolved in an appropriate amount of anhydrous dimethyl sulfoxide, and reacted overnight at room temperature. After the reaction was complete, unreacted substances were removed by dialyzing. The final product, BOD-GGT, was obtained by lyophilization.

[0061] Similarly, BOD-PEG can be obtained by reacting BOD-N3 and 2-[2-[2-(2-prop-1-yloxy)ethoxy]ethoxy]ethanol under the same reaction conditions and post-treatment.

[0062] 5. Characterization by proton nuclear magnetic resonance spectroscopy The product was characterized by proton NMR spectroscopy, as shown in the following figure. Figure 4 As shown, the peak integrals of each hydrogen atom are correctly assigned, indicating that BOD-GGT was synthesized in this embodiment.

[0063] 6. Characterization of optical properties The optical properties of BOD-GGT were characterized using a multifunctional enzyme-linked immunosorbent assay (ELISA) device. First, the UV-Vis absorption spectrum of the probe in DMSO was measured; then, its characteristic absorption peak was used as the excitation wavelength to record the corresponding fluorescence emission spectrum. Further, a series of gradient solutions with concentrations ranging from 3 to 15 μM were prepared, and a molar extinction coefficient curve was established based on the linear relationship between absorbance at the maximum absorption wavelength and concentration.

[0064] The results are as follows Figures 5-7As shown, the optimal excitation of BOD-GGT is approximately 700 nm, and the optimal emission is approximately 735 nm.

[0065] 7. Enzyme digestion characterization of GGT hydrolyzable fragments Using nuclear magnetic resonance hydrogen spectroscopy (NMR) 1 Enzymatic characterization of the GGT hydrolyzable fragment obtained in Example 1 by ¹H NMR. The reaction system was prepared by adding 10 U GGT enzyme to PBS buffer prepared with deuterated H₂O. Subsequently, 5 mg of the test fragment was dissolved in the enzyme solution and incubated at 37°C for 4 h.

[0066] The results are as follows Figure 8 As shown, comparing the spectra before and after enzyme treatment reveals a significant shift in the chemical shift of hydrogen at key positions, confirming the successful occurrence of the GGT-mediated hydrolysis reaction.

[0067] Example 2: Cell uptake experiment 1. Rapid cell entry validation of BOD-GGT BxPC-3 cells were fed at a concentration of 1.5 × 10⁻⁶. 5 Cells were seeded in 12-well plates and cultured overnight. After complete cell adhesion, the original culture medium was removed. The medium was then replaced with fresh medium containing BOD-GGT (5 μM) and incubated for 5 min, 10 min, 15 min, and 30 min, respectively. After incubation, cells were washed three times with 1 mL of pre-chilled PBS, triedpsinized, centrifuged, washed three more times with PBS, and resuspended. Intracellular BOD uptake and fluorescence intensity were assessed by flow cytometry to evaluate the probe uptake kinetics of BxPC-3 cells.

[0068] The results are as follows Figure 9 As shown, the positive rate of BOD-GGT reached 43% after 5 minutes of incubation, 86% after 10 minutes, and climbed to 96% after 15 minutes. This indicates that BOD-GGT has the ability to be rapidly taken up by BxPC-3 cells.

[0069] 2. Uptake in different cell lines To verify the targeting of the probe, this study compared the differences in material uptake between BxPC-3 (GGT high expression) and NIH-3T3 (GGT low expression) cells.

[0070] Five experimental groups were set up, including 3T3-GGT: NIH-3T3 cells were fed at a rate of 1.5 × 10⁻⁶. 5 Cells were seeded in 12-well plates and incubated with BOD-GGT (5 μM) for 3 h; 3T3-PEG: NIH-3T3 cells were incubated at 1.5 × 10⁻⁶ cells per well. 5Cells were seeded in 12-well plates and incubated with BOD-PEG (5 μM) for 3 h; Bx-PEG: BxPC-3 cells were incubated at 1.5 × 10⁻⁶ cells / well. 5 Cells / wells were seeded into 12-well plates and incubated with BOD-PEG (5 μM) for 3 h; Bx-GgsTop-GGT: BxPC-3 cells were incubated at 1.5 × 10⁻⁶ cells / well. 5 Cells / wells were seeded in 12-well plates and pretreated with GGsTop (10 μM) for 24 h to inhibit GGT activity, followed by incubation with BOD-GGT (5 μM) for 3 h; Bx-GGT: BxPC-3 cells were seeded at 1.5 × 10⁻⁶ cells / well. 5 Cells were seeded into 12-well plates and incubated with BOD-GGT for 3 h. After incubation in each experimental group, cells were resuspended by trypsin digestion and analyzed by flow cytometry.

[0071] The results are as follows Figure 10 As shown, the average fluorescence intensity of the BxPC-3 group was significantly higher than that of the NIH-3T3 group. The fluorescence intensity within BxPC-3 cells was approximately 1.84 times that of mouse fibroblast NIH-3T3 cells, making it suitable for imaging tumor cells with high GGT expression. This uptake advantage could be effectively inhibited by GGsTop. Furthermore, BxPC-3 showed significantly better uptake of BOD-GGT from the experimental group compared to the control group, BOD-PEG.

[0072] The above results demonstrate that the cellular uptake of BOD-GGT is highly GGT-dependent.

[0073] Example 3: BxPC-3 cell sphere permeation experiment To further simulate the material's permeability in three dimensions, a tumor sphere model of BxPC-3 was constructed. The method was referenced in the literature (Zhou Q, ...). et al . Enzyme-Activatable Polymer-Drug Conjugate AugmentsTumour Penetration and Treatment Efficacy. Nat Nanotechnol (2019, 14 (8): 799-809.) Cell spheres were constructed and transferred to 96-well plates after cell spheroidization. 100 μL of serum-containing medium was added to each well, and the cells were cultured for three days until the spheres stabilized. The old medium was then removed, and 100 μL of medium containing 10 μM dye was added and incubated with the cell spheres for 6 h. The cell spheres were then transferred to a confocal dish containing fresh medium, and imaging was performed using laser confocal microscopy with Z-stack tomography at 25 μm intervals. Linear fluorescence intensity (grayscale value) analysis was performed on the largest cross-section of the tumor spheres in the images.

[0074] The results are as follows Figure 11 and Figure 12 As shown, at 6 hours, BOD-GGT had completely penetrated into the tumor sphere, while BOD-PEG had only penetrated a small portion, with most remaining at the sphere's edge. This result further demonstrates that BOD-GGT has a stronger penetrating ability than BOD-PEG.

[0075] Example 4: In vivo imaging experiment of tumor-bearing rats When the tumor volume of BALB / c nude mice bearing BxPC-3 subcutaneous tumors reached 200 mm... 3 At approximately 10:00 AM, the fluorescent dyes BOD-GGT or BOD-PEG (5 μmol / kg) were injected via tail vein injection. Fluorescence images were acquired using a small animal in vivo imaging system (IVIS) at 0.5 h, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h (since the excitation channel of the IVIS system is fixed, the parameters closest to the optical properties of BOD-GGT were selected in this experiment: excitation wavelength of 660 nm, emission wavelength of 710 nm, and exposure time of 1 s), and the average fluorescence value of the tumor region was quantitatively analyzed.

[0076] The results are as follows Figure 13 and Figure 14 As shown, BOD injected via the tail vein rapidly accumulated at the tumor site within 0.5 h, reaching its peak value. At this point, the tumor fluorescence signal of the experimental group BOD-GGT was approximately 2.4 times that of the control group BOD-PEG, after which the signal gradually weakened. Furthermore, due to the active penetration function of the fluorescent probe, it exhibits a certain degree of intratumoral accumulation. The tumor signal intensity and accumulation amount in the BOD-GGT group were significantly superior to those in the BOD-PEG group. In vivo imaging results showed that a strong fluorescence signal remained within the tumor even 72 h after metabolism. This is attributed to its superior tumor cell uptake efficiency and tissue penetration ability.

[0077] Example 5: Metabolic Analysis 1. Organ distribution experiment A BxPC-3 mouse model of subcutaneous pancreatic cancer was established. The tumor volume reached 200 mm². 3 At approximately 10:00 AM, mice were injected with either the fluorescent dye BOD-GGT or BOD-PEG (5 μmol / kg) via tail vein injection. Mice were euthanized at 0.5 h, 6 h, 24 h, 48 h, and 72 h after administration, and the heart, liver, spleen, lungs, kidneys, and tumors were dissected. Fluorescence images were acquired using IVIS (excitation wavelength 660 nm, emission wavelength 710 nm, exposure time 1 s), and the average fluorescence values ​​of each organ and tumor region were quantitatively analyzed.

[0078] The results are as follows Figure 15 and Figure 16 As shown, the BOD-GGT group exhibited significant fluorescence enrichment at the tumor site, with its average fluorescence intensity significantly higher than that of the control group, BOD-PEG. Over time, the fluorescence signal decay rate of BOD-GGT within the tumor was significantly slower than that of BOD-PEG, with noticeable signal retention still detectable even after 72 hours, indicating that this material has an excellent retention effect within the tumor. Furthermore, by comparing the distribution in major organs, we observed that BOD-GGT exhibited good tumor selectivity, and both BOD-GGT and BOD-PEG are primarily metabolized by the liver and kidneys.

[0079] 2. Plasma clearance experiment To evaluate the stability and clearance rate of the probe in the circulatory system, healthy Balb / c mice were selected as experimental subjects. Fluorescent dyes BOD-GGT or BOD-PEG (5 μmol / kg) were injected via tail vein. Blood samples were collected via orbital sampling at predetermined time points (0, 1, 3, 6, 12, 24, and 48 hours after administration). The collected blood was centrifuged to obtain plasma. Fluorescence images were acquired using IVIS (excitation wavelength 660 nm, emission wavelength 710 nm, exposure time 1 s), and the fluorescence intensity in the plasma was measured. The blood drug concentration at each time point (expressed as a percentage of the initial concentration of BOD) was calculated based on the fluorescence values.

[0080] The curve of blood concentration changing over time is as follows: Figure 17 As shown in the figure. Experiments show that the fluorescent probe BOD-GGT provided by this invention has a short blood half-life of only about 1.16 h, and the residual probe concentration in the blood is less than 10% after 24 hours, indicating that the probe can be effectively cleared from the blood circulation. Compared with BOD-GGT, BOD-PEG has a slightly longer blood circulation time. This may be because the modification of the PEG chain segment enhances the cyclic stability of the molecule to some extent, but both show a good metabolic trend. This rapid clearance pharmacokinetic characteristic has the advantage of reducing systemic toxicity.

[0081] Example 6: Intraoperative navigation experiment A BxPC-3 mouse model of subcutaneous pancreatic cancer was established. The tumor volume reached 200 mm². 3At approximately 10:00 AM, the surface skin of the tumor was surgically incised to expose the tumor. The BOD-GGT prepared according to this invention was dissolved in PBS containing 10% DMSO to prepare a 1 mM spray solution. The solution was sprayed onto the exposed tumor and surrounding normal tissue using a micro-spray device. After spraying, the area was incubated in a dark environment for 15-30 minutes, followed by imaging observation using a near-infrared fluorescence imaging system (excitation wavelength 660 nm, emission wavelength 710 nm).

[0082] Experimental results are as follows Figure 18 As shown, the tumor area exhibited significant fluorescence signal under in-situ spraying mode, and the fluorescence distribution closely matched the surgically exposed tumor boundary. Quantitative analysis revealed a fluorescence ratio (T / N) of 4.05 between the tumor tissue and the surrounding normal tissue. This demonstrates that BOD-GGT can achieve precise visualization of the tumor boundary through local spraying.

[0083] Example 7: Safety Evaluation To further assess the biocompatibility of the material in vivo, after the in vivo imaging experiment, we harvested the major organs (heart, liver, spleen, lung, and kidney) from each group of mice and performed standardized HE-stained tissue section analysis.

[0084] The results are as follows Figure 19 As shown, microscopic observation results indicate that, compared with the PBS control group, the organs and tissues of mice injected with BOD-GGT and BOD-PEG were intact, and the cell nuclei were clearly and densely arranged. No obvious abnormal lesions such as tissue necrosis, inflammatory cell infiltration, tissue edema or fibrosis were observed.

[0085] The aforementioned pathological evaluation data fully confirm that, at this experimental dose, the probe has good biocompatibility and no significant systemic toxic side effects.

[0086] It should be understood that the application of the present invention is not limited to the examples above. Those skilled in the art can make improvements or modifications based on the above description, and all such improvements and modifications should fall within the protection scope of the appended claims.

Claims

1. A γ-glutamyl transpeptidase-responsive fluorescent probe for enhanced tumor penetration, characterized in that, The molecular structure of the fluorescent probe is shown in formula (Ⅰ). (Ⅰ), Where n is between 2 and 20.

2. The γ-glutamyl transpeptidase-responsive tumor-penetrating fluorescent probe as described in claim 1, characterized in that, n is 3.

3. The method for preparing the fluorescent probe as described in claim 1 or 2, characterized in that, Includes the following steps: (1) Under alkaline conditions, a nucleophilic substitution reaction was carried out between tert-butyl bromoacetate and Aza-BODIPY, and after deprotection by trifluoroacetic acid, BOD-COOH with a carboxyl group was obtained; subsequently, it was amidated with terminal azidated polyethylene glycolamine to obtain BOD-N3; (2) Boc-L-2-aminobutyric acid undergoes an amidation reaction with but-3-yn-1-amine, followed by deprotection with trifluoroacetic acid to obtain an intermediate product, which then undergoes an amidation reaction with Boc-L-glutamic acid-1-tert-butyl ester, and after deprotection, GGT-responsive hydrolysis molecules are obtained. (3) The fluorescent probe was prepared by reacting BOD-N3 with GGT-responsive hydrolysate via an azide-alkyne cycloaddition reaction.

4. The preparation method according to claim 3, characterized in that, In steps (1) and (2), prior to the amidation reaction, BOD-COOH, Boc-L-2-aminobutyric acid, or Boc-L-glutamic acid-1-tert-butyl ester are activated by N,N′-carbonyldiimidazole.

5. The use of the fluorescent probe as described in claim 1 or 2 in the preparation of tumor imaging reagents.

6. The application as described in claim 5, characterized in that, The tumor imaging reagent comprises the fluorescent probe and a pharmaceutically acceptable solvent, wherein the solvent is water, physiological saline, buffer solution, or an aqueous solution containing 1%-20% by volume of an organic co-solvent.

7. The application as described in claim 5, characterized in that, The tumor imaging reagent is used to prepare tumor diagnostic kits or intraoperative navigation kits.

8. The application as described in claim 7, characterized in that, The tumor imaging reagent is an intravenous injection preparation or a spray.

9. The application as described in claim 5, characterized in that, The tumor is a tumor that highly expresses γ-glutamyl transpeptidase.

10. The application as described in claim 9, characterized in that, The tumor is pancreatic cancer.